Interleukin 29

IFNL1
Available structures
PDB	Human UniProt search: PDBe RCSB
List of PDB id codes
	3OG6, 3OG4
Identifiers
Aliases	IFNL1, IL-29, IL29, interferon, lambda 1, interferon lambda 1
External IDs	OMIM: 607403 HomoloGene: 131189 GeneCards: IFNL1
Gene location (Human)
Chr.	Chromosome 19 (human)[1]
End	39,298,673 bp[1]
Gene ontology
Molecular function	• cytokine activity; • interleukin-28 receptor binding; • receptor binding;
Cellular component	• interleukin-28 receptor complex; • intracellular; • extracellular region; • extracellular space;
Biological process	• JAK-STAT cascade; • negative regulation of interleukin-5 production; • positive regulation of tyrosine phosphorylation of STAT protein; • positive regulation of interferon-gamma production; • negative regulation of interleukin-13 production; • positive regulation of transcription, DNA-templated; • positive regulation of immune response; • defense response to virus; • negative regulation of type 2 immune response; • innate immune system; • negative regulation of transcription, DNA-templated; • positive regulation of MHC class I biosynthetic process; • negative regulation of memory T cell differentiation; • negative regulation of T cell differentiation; • positive regulation of JAK-STAT cascade; • negative regulation of cell proliferation; • regulation of receptor activity; • cytokine-mediated signaling pathway;
	Sources:Amigo / QuickGO
Orthologs
	282618
	n/a
	ENSG00000182393
	n/a
	Q8IU54
	n/a
	NM_172140
	n/a
	NP_742152
	n/a
	Wikidata
View/Edit Human

Interleukin-29 (IL-29) is a protein that in humans is encoded by the IL29 gene that resides on chromosome 19.[3][4]

IL-29 is a member of the helical cytokine family and is a type III interferon.[5] It is also known as IFNλ1 and is highly similar in amino acid sequence to the IL-28, the other type III interferon. IL-29 plays an important role in host defenses against microbes and its gene is highly upregulated in cells infected with viruses. IL29 is not present in the mouse genome.

References

GRCh38: Ensembl release 89: ENSG00000182393 - Ensembl, May 2017
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: interleukin 29 (interferon".
Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM (January 2003). "IL-28, IL-29 and their class II cytokine receptor IL-28R". Nature Immunology. 4 (1): 63–8. doi:10.1038/ni873. PMID 12469119.
Vilcek J (January 2003). "Novel interferons". Nature Immunology. 4 (1): 8–9. doi:10.1038/ni0103-8. PMID 12496969.

Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD (October 2008). "Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication". The Journal of Biological Chemistry. 283 (44): 30079–89. doi:10.1074/jbc.M804296200. PMC 2662072. PMID 18757365.
Li MC, Wang HY, Wang HY, Li T, He SH (April 2006). "Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells". Acta Pharmacologica Sinica. 27 (4): 453–9. doi:10.1111/j.1745-7254.2006.00292.x. PMID 16539846.
Megjugorac NJ, Gallagher GE, Gallagher G (December 2009). "Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29)". Journal of Leukocyte Biology. 86 (6): 1359–63. doi:10.1189/jlb.0509347. PMID 19759281.
Uzé G, Monneron D (2007). "IL-28 and IL-29: newcomers to the interferon family". Biochimie. 89 (6–7): 729–34. doi:10.1016/j.biochi.2007.01.008. PMID 17367910.
Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ (April 2009). "Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages". Journal of Virology. 83 (8): 3834–42. doi:10.1128/JVI.01773-08. PMC 2663280. PMID 19193806.
Magracheva E, Pletnev S, Kotenko S, Li W, Wlodawer A, Zdanov A (January 2010). "Purification, crystallization and preliminary crystallographic studies of the complex of interferon-lambda1 with its receptor". Acta Crystallographica Section F. 66 (Pt 1): 61–3. doi:10.1107/S1744309109048817. PMC 2805539. PMID 20057073.
Stoltz M, Klingström J (September 2010). "Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection". Journal of Virology. 84 (18): 9140–8. doi:10.1128/JVI.00717-10. PMC 2937636. PMID 20592090.
Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J (November 2005). "IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression". American Journal of Physiology. Gastrointestinal and Liver Physiology. 289 (5): G960–8. doi:10.1152/ajpgi.00126.2005. PMID 16051921.
Pekarek V, Srinivas S, Eskdale J, Gallagher G (March 2007). "Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner". Genes and Immunity. 8 (2): 177–80. doi:10.1038/sj.gene.6364372. PMID 17252004.
Li M, Liu X, Zhou Y, Su SB (July 2009). "Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses". Journal of Leukocyte Biology. 86 (1): 23–32. doi:10.1189/jlb.1208761. PMID 19304895.
Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G (January 2007). "Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29)". Genes and Immunity. 8 (1): 13–20. doi:10.1038/sj.gene.6364348. PMID 17082759.
Wang J, Oberley-Deegan R, Wang S, Nikrad M, Funk CJ, Hartshorn KL, Mason RJ (February 2009). "Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection". Journal of Immunology. 182 (3): 1296–304. doi:10.4049/jimmunol.182.3.1296. PMC 4041086. PMID 19155475.
Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV (April 2006). "Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma". Cancer Research. 66 (8): 4468–77. doi:10.1158/0008-5472.CAN-05-3653. PMID 16618774.
Osterlund P, Veckman V, Sirén J, Klucher KM, Hiscott J, Matikainen S, Julkunen I (August 2005). "Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells". Journal of Virology. 79 (15): 9608–17. doi:10.1128/JVI.79.15.9608-9617.2005. PMC 1181545. PMID 16014923.
Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM (July 2008). "IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity". Cancer Biology & Therapy. 7 (7): 1109–15. doi:10.4161/cbt.7.7.6192. PMC 2435218. PMID 18698163.
Mennechet FJ, Uzé G (June 2006). "Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells". Blood. 107 (11): 4417–23. doi:10.1182/blood-2005-10-4129. PMID 16478884.
Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat R (May 2008). "Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes". Journal of Leukocyte Biology. 83 (5): 1181–93. doi:10.1189/jlb.0807525. PMID 18281438.
Novak AJ, Grote DM, Ziesmer SC, Rajkumar V, Doyle SE, Ansell SM (December 2008). "A role for IFN-lambda1 in multiple myeloma B cell growth". Leukemia. 22 (12): 2240–6. doi:10.1038/leu.2008.263. PMC 2771776. PMID 18830264.
Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K (December 2009). "Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines". Genes and Immunity. 10 (8): 702–14. doi:10.1038/gene.2009.72. PMID 19798076.
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY (April 2010). "Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study". Gastroenterology. 138 (4): 1338–45, 1345.e1–7. doi:10.1053/j.gastro.2009.12.056. PMID 20060832.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[refGRCh38Ensembl-1] GRCh38: Ensembl release 89: ENSG00000182393 - Ensembl, May 2017

[2] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[entrez-3] "Entrez Gene: interleukin 29 (interferon".

[pmid12469119-4] Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM (January 2003). "IL-28, IL-29 and their class II cytokine receptor IL-28R". Nature Immunology. 4 (1): 63–8. doi:10.1038/ni873. PMID 12469119.

[pmid12496969-5] Vilcek J (January 2003). "Novel interferons". Nature Immunology. 4 (1): 8–9. doi:10.1038/ni0103-8. PMID 12496969.

Interleukin 29

References

Further reading